GRCL News and Press, Gracell Biotechnologies Inc. From 05/15/23

Presenting longer-term follow-up data from investigator-initiated trial (IIT) evaluating BCMA/CD19 dual-targeting FasTCAR-T GC012F in relapsed/refractory multiple myeloma (RRMM) at 2023 ASCO and EHA2023 On track to commence a Phase 1b/2 clinical trial in U.S. and a Phase 1/2 clinical tria...

Gracell Biotechnologies Initiates Investigational Study Evaluating GC012F for Treatment of Refractory Systemic Lupus Erythematosus (SLE) PR Newswire Gracell announces start of investigator-initiated trial to expand clinical evaluation of FasTCAR-T GC012F into autoimmune diseas...

Gracell Biotechnologies to Present Clinical Data on BCMA/CD19 Dual-Targeting FasTCAR-T GC012F in RRMM and B-NHL and Donor-Derived CAR-T GC007g in B-ALL at EHA2023 Congress PR Newswire First disclosure of data from Phase 1 study of the donor-derived allogeneic CAR-T GC007g show...

SAN DIEGO and SUZHOU, China and SHANGHAI, China, May 02, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of ...

Gracell Biotechnologies to Present Updated Clinical Data on BCMA/CD19 Dual-Targeting FasTCAR-T GC012F at 2023 ASCO Annual Meeting PR Newswire SAN DIEGO, Calif. , and SUZHOU and SHANGHAI, China , April 26, 2023 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gr...

SAN DIEGO and SUZHOU, China and SHANGHAI, China, April 25, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment o...

2023-04-14 13:30:11 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch for a full list of events planned for the week or the Seeking Alpha earnings calendar for com...

2023-03-20 01:10:00 ET Summary Livzon entered a $127.5 million agreement for China rights to a gastroesophageal reflux disease (GERD) therapy from Onconic Therapeutics of Korea. Gracell Biotech announced in a press release that it had entered an unusual, non-exclusive global deal ...

2023-03-13 12:03:10 ET Gracell Biotechnologies Inc. (GRCL) Q4 2022 Earnings Conference Call March 13, 2023, 08:00 AM ET Company Participants Kevin Yili Xie - Chief Financial Officer William Wei Cao - Founder, Chairman, and Chief Executive Officer Wendy Li - Chief...

2023-03-13 07:41:15 ET Gracell Biotechnologies press release ( NASDAQ: GRCL ): Q4 GAAP EPS of -$0.06 beats by $0.07 . As of December 31, 2022, the Company had RMB1,458.2 million (US$211.4 million) in cash and cash equivalents and short-term investments. For f...